Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2020 - 12 - 03 save search
IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
Published: 2020-12-03 (Crawled : 19:00) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
|
| O: 1.14%
H: 4.49%
C: -1.12%
cancer therapy ovarian cancer phase 2 t-cell
F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial
Published: 2020-12-03 (Crawled : 15:00) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: -4.67%
H: 8.23%
C: 0.94%
trial phase 3 phase 1 phase 2
Aemetis Biogas Awarded $7.8 Million in CDFA Grants for Phase 2 RNG Dairy Digester Project
Published: 2020-11-20 (Crawled : 14:52) - globenewswire.com
AMTX | $3.64 -3.96% -4.12% 760K
|
Process Industries
|
| O: 1.49%
H: 7.32%
C: 0.49%
phase 2 granted grant awards
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
Published: 2020-12-03 (Crawled : 12:01) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -0.6%
H: 4.0%
C: 0.4%
trial treatment phase 2 psoriasis enroll
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
Published: 2020-10-13 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 5.11%
H: 13.77%
C: 3.51%
covid vaccine trial phase 3 phase 1 phase 2
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
Published: 2020-09-23 (Crawled : 09:33) - globenewswire.com
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: -1.36%
H: 6.7%
C: 3.79%
phase 3 phase 1 phase 2
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis
Published: 2020-08-20 (Crawled : 09:08) - globenewswire.com
AQST | $4.505 14.92% 12.99% 5.8M
|
Health Technology
|
| O: 0.24%
H: 8.88%
C: 4.44%
liver trial treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.